Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (time to treatment failure) (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine may leads to higher time to treatment failure (any reason related to treatment)… compared with phenytoin (time to treatment failure) (low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to first seizure after randomisationAll participants Range of compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to first seizure after randomisation Subgroup: focal onset… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) ‐ stratified by epilepsy type: generalised onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to first seizure after randomisationSubgroup: generalisedonset… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Time to achieve 12‐month remissionAll participants Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to achieve 12‐month remissionAll participants Range of compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to achieve 12‐month remissionSubgroup: focal onset seizures… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to achieve 12‐month remissionSubgroup: generalisedonset tonic… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency Number of seizures · patients with drug‐resistant epilepsy
1 finding from 1 review
Seizure freedom · patients with drug‐resistant epilepsy
1 finding from 1 review
Treatment withdrawal · patients with drug‐resistant epilepsy
1 finding from 1 review
Withdrawals due to adverse events · patients with drug‐resistant epilepsy
1 finding from 1 review
50% reduction in generalised‐onset seizure frequency Not measured · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% reduction in focal‐onset seizure frequency Not measured · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with focal epilepsy
Losigamone probably leads to higher 50% or greater reduction in seizure frequency compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with focal epilepsy
Losigamone probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · people with focal epilepsy
Losigamone showed no clear difference in the proportion of participants experiencing any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Dizziness · people with focal epilepsy
Losigamone probably leads to higher adverse event (dizziness) compared with placebo (moderate certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · patients between 3 to 15 months of age with West syndrome
The review found no eligible studies for this question.
1 finding from 1 review
Complete cessation of seizures 9 days · patients between 3 to 15 months of age with West syndrome
It is very uncertain whether sulthiame add‐on changes complete cessation of seizures during compared with placebo (very low certainty).
1 finding from 1 review